Irinotecan with or without capecitabine as a beyond 2nd line regime for esophago-gastric adenocarcinomas
Authors
Hapuarachi, Sonal BDawod, Mohammed
Weaver, Jamie M
Shaheen, Fadhel
Khan, Adeel
Hubner, Richard A
Waddell, Thomas
Mansoor, Was
Affiliation
Christie NHS Foundation Trust, ManchesterIssue Date
2020
Metadata
Show full item recordAbstract
Background: Purpose: The aim of this retrospective study was to assess the efficacy and toxicity of irinotecan +/- capecitabine for patients with metastatic esophago-gastric (EG) adenocarcinomas previously treated with at least two chemotherapy regimens including platinum-based, fluoropyramidines and taxanes. Introduction: Treatment for metastatic EG cancer beyond 2nd line remains controversial. Recently, the TAGS phase III trial (Shitara et al., 2018) showed overall survival benefit with Trifluridine/tipiracil of 2.1 months compared to placebo as a third line. Apatinib is also approved for use as third line in China (Li et al., 2013). Based on minimal evidence (Kang et al., 2013), irinotecan in combination with capecitabine is used in the UK. We performed a retrospective study to assess the efficacy and toxicity of irinotecan as a beyond 2nd line regime in metastatic EG adenocarcinomas in one of Europe’s largest cancer centres, The Christie. Methods: Data was collected retrospectively from all metastatic EG adenocarcinoma patients who were treated with irinotecan +/- capecitabine as a beyond 2nd line palliative treatment at the Christie Hospital from January 2014 to December 2019. Irinotecan was either given 2 or 3 weekly at dose of 180 mg/m² with or without capecitabine 800 mg/m². Response rate (RR) was calculated according to RECIST version 1.1, overall survival measured and toxicity data collected. Results: Fifty-six patients received irinotecan as beyond 2nd line palliative chemotherapy. Out of the thirty-seven patients with measurable disease on their scans, the overall response rate was 8.1% and the disease control rate was 51.4% as per RECIST 1.1. Median overall survival was 5 months (95% CI 4.2-5.8). The presence of grade 3-4 toxicities was 16% (9 patients) and included neutropenia, fatigue, nausea and diarrhea. On average, 3.7 cycles were administered, 32% (18 patients) required dose reductions, mainly secondary to grade 2 diarrhea and fatigue. Conclusions: Irinotecan in combination with capecitabine is efficacious as a beyond 2nd line regime in metastatic EG with an acceptable toxicity profile with a limited role in patients with resistant disease to first line platinum-based chemotherapies with fluoropyramidines.Citation
Hapuarachi SB, Dawod M, Weaver J, Shaheen F, Khan A, Hubner R, et al. Irinotecan with or without capecitabine as a beyond 2nd line regime for esophago-gastric adenocarcinomas. Journal of Clinical Oncology. 2020;38(15_suppl):e16545-e.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2020.38.15_suppl.e16545Additional Links
https://dx.doi.org/10.1200/JCO.2020.38.15_suppl.e16545Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2020.38.15_suppl.e16545